TP53 and acute leukemia: Here, we show that in the presence of DSB-inducing therapies, IR and topoisomerase II inhibitors, M3814 potentiates the ATM/p53 signaling in acute leukemia cells leading to elevation of p53 protein levels and transcriptional activity.